Regentis Biomaterials Ltd. (RGNT)

Overview

Regentis Biomaterials Ltd. is a pioneering regenerative medicine company committed to innovating tissue repair solutions aimed at restoring health and enhancing the quality of life for patients. Established in 2004 and based in Herzliya, Israel, the company has concentrated its efforts on developing advanced orthopedic treatments utilizing its proprietary Gelrin platform. This platform features biodegradable hydrogel implants designed to effectively regenerate damaged or diseased tissues, specifically focusing on the knee area where painful injuries and articular cartilage issues are prevalent.

Products and Services

• GelrinC

  GelrinC is Regentis Biomaterials' flagship product, a cell-free hydrogel designed for knee applications. It is formulated as an off-the-shelf solution and is utilized as an implant that can be cured directly in the knee to address various cartilage injuries and restore functionality. By mimicking the natural properties of cartilage, GelrinC effectively alleviates pain and supports healing in injured areas.

• Gelrin Platform

  This platform encompasses a range of degradable hydrogel technologies that facilitate tissue regeneration in various orthopedic applications. The Gelrin platform is characterized by its versatility, allowing for modifications that cater to specific tissue types and injury scenarios, thereby optimizing the healing process across different medical conditions.

• Orthopedic Treatment Solutions

  Regentis is dedicated to expanding its product line to include a variety of orthopedic treatments that leverage the unique properties of their hydrogels. This ongoing commitment ensures that patients have access to cutting-edge solutions that can improve recovery times, enhance mobility, and ultimately lead to a better quality of life following orthopedic injuries.